Bristol Myers Squibb Co patents expiration
1. Abraxane patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8314156 | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(2 months from now) | |
| US8138229 | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(2 months from now) | |
| US7923536 | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(2 months from now) | |
|
US8138229 (Pediatric) | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(8 months from now) | |
|
US7923536 (Pediatric) | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(8 months from now) | |
|
US8314156 (Pediatric) | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(8 months from now) | |
| US7820788 | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(1 year, 29 days from now) | |
|
US7820788 (Pediatric) | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(1 year, 6 months from now) | |
| US9101543 | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(2 years from now) | |
| US8268348 | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(2 years from now) | |
| US7758891 | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(2 years from now) | |
| US8034375 | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US9101543 (Pediatric) | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US7758891 (Pediatric) | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8268348 (Pediatric) | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8034375 (Pediatric) | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(3 years from now) | |
| US9597409 | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Mar, 2032
(8 years from now) | |
| US9393318 | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Mar, 2032
(8 years from now) | |
|
US9597409 (Pediatric) | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
|
US9393318 (Pediatric) | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
| US9511046 | BRISTOL MYERS SQUIBB CO | Methods of treating pancreatic cancer |
Jan, 2034
(10 years from now) | |
|
US9511046 (Pediatric) | BRISTOL MYERS SQUIBB CO | Methods of treating pancreatic cancer |
Jul, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer; Treatment of pancreatic cancer; Treatment of breast cancer
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic